Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
7.310
+0.130 (+1.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NeoGenomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 30, 2025
Via
ACCESS Newswire
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
June 30, 2025
From
NeoGenomics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 24, 2025
Via
ACCESS Newswire
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
June 24, 2025
From
NeoGenomics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
May 28, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
May 22, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in Upcoming June Investor Conferences
May 20, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Pays Off 1.25% Convertible Senior Notes
May 01, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports First Quarter 2025 Results
April 29, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
April 22, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
April 08, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Completes Acquisition of Pathline
April 07, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
April 01, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
March 18, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
March 10, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in Upcoming Investor Conferences
February 24, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
February 18, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
January 29, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
January 15, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
January 14, 2025
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
From
Adaptive Biotechnologies
Via
GlobeNewswire
NeoGenomics Announces Chief Executive Officer Succession
January 10, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
December 11, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
December 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
November 19, 2024
From
NeoGenomics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.